Stock Analysis
Jazz Pharmaceuticals, Inc.JAZZ
P/E 14.51×· 5Y range 12.37–538.02×· bottom 9% of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy26 analystsP/E 14.5× sits at the 9th percentile of its 5.059548254620124-year history.
Cash covers 32% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Profitability77
- Quality71
Risks
- Growth37
- Financial Health40
Mixed business trading cheap — priced for skepticism.
Bull Case
- ✓ROE 21.8% — efficient capital deployment
- ✓P/E 14.5× at bottom 9% of 5-year history
What's happening with JAZZ
Profile
Strong valuation and profitability; moat, growth and financial health lag behind.
How is each axis scored?
- Valuation82/100 · Strong
- P/E vs own history (9th pct)25/25
- FCF yield (11.6%)25/25
- P/S (3.0x)20/25
- EV/EBIT (18.5x)12/25
- Growth37/100 · Weak
- Revenue CAGR (8.4%)12/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (55.3%)25/25
- Profitability77/100 · Strong
- ROIC (9.8%)12/25
- ROE (21.8%)20/25
- Net margin (20.4%)25/25
- Operating margin (19.5%)20/25
- Financial Health40/100 · Weak
- Altman Z (1.57)10/25
- Current ratio (1.86)18/25
- Interest coverage (-2.2x)0/25
- Net cash / debt (D/A 25%)12/25
- Quality71/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-3.68)25/25
- FCF conversion (169%)25/25
- Margin stability (σ 18.6%)6/25
- Moat25/100 · Weak
- ROIC >12% years (2/10 yrs)0/25
- Median gross margin (15.1%)0/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -10.7%)0/25
Risk Flags
- ⚠Altman Z 1.6 — distress-zone balance sheet
- ⚠SBC 6.7% of revenue — real dilution cost
- ⚠3 loss-making years in recent history
- ⚠Interest coverage -2.2× — thin debt cushion
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Show more
Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Headquarters: DUBLIN · Employees: 2,890 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
82AP/E (TTM)14.5xA
Grade A: CheapPrice / TTM EPS (own statements) — vs own 5Y history: 12.4x–538.0x · 9th pct
P/FCF10.1xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield11.6%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 6.3%–25.4% · 37th pct
P/S (TTM)2.97xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.5x–3.7x · 85th pct
EV/EBIT18.5xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 11.7x–335.2x · 22nd pct
EV/Sales3.6xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E9.4xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.16xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.33A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
77B+ROIC9.8%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE21.8%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA8.2%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin20.4%A
Grade A: HighNet Income / Revenue
Operating Margin19.5%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin19.5%D
Grade D: LowGross Profit / Revenue
FCF Margin34.6%A
Grade A: HighFCF / Revenue
True FCF Margin27.9%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
37DRevenue CAGR8.4%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth55.3%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+12.0%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income32.6%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue6.7%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
40D+Altman Z-Score1.57D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.86xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.49xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-2.2xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment1.8yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT3.3xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity1.00xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.32xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
71B+Piotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-3.68A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion169.2%A
Grade A: StrongFCF / Net Income
Margin Stability18.6%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue1.5%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.40xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
GALA RENEE D Filed | GALA RENEE D | SellOpen market sale | -2000 | |
COZADD BRUCE C Filed | COZADD BRUCE C | SellOpen market sale | -6000 | |
Patil Neena M Filed | Patil Neena M | SellOpen market sale | -1200 | |
Henderson Mary Elizabeth Filed | Henderson Mary Elizabeth | Tax withholding | -15 | |
Henderson Mary Elizabeth Filed | Henderson Mary Elizabeth | Tax withholding | -1412 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
GALA RENEE D Filed | GALA RENEE D | SellOpen market sale | -2000 | |
GALA RENEE D Filed | GALA RENEE D | Tax withholding | -1967 | |
COZADD BRUCE C Filed | COZADD BRUCE C | SellOpen market sale | -6000 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
25EROIC >12% Years2/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)15.1%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-10.7%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$14.49
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$33.95
Cash & short-term investments per share (Finnhub)
Book Value / Share$74.10
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$4.33B
Total debt obligations (short + long term)
Cash & Equiv.$1.39B
Cash and short-term investments
Net Debt$2.94B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$4.32B
Shareholders' equity (book value)
Asset / Liability1.59xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$13.66B
Current Market Capitalization
Beta0.37B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Jazz Pharmaceuticals, Inc. (JAZZ)
JAZZ is down 1.95% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Jazz Pharmaceuticals, Inc.. Altman Z-Score of 1.57 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -3.68 suggests a low likelihood of earnings manipulation. Jazz Pharmaceuticals, Inc. converts about 35% of revenue into free cash flow — strong cash generation.
- Takes ~1.8 years to repay net debt from free cash flow.
- Interest coverage of -2.2× leaves little room for earnings shocks.
- Jazz Pharmaceuticals, Inc. posted a net loss in 3 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 82/100, JAZZ trades near the cheapest end of its own historical range (P/E 14.5).
- Return on equity of 21.8% is well above the market average.
See how JAZZ ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all JAZZ moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 213.99 | +2.07% | 2.07 |
| Oct 15 | After-hours | 216.17 | +3.11% | 2.81 |
| Oct 8 | Regular | 223.54 | -3.31% | -2.52 |
| Oct 8 | After-hours | 222.45 | -3.78% | -2.91 |
Frequently Asked Questions about JAZZ
What is the current Jazz Pharmaceuticals, Inc. (JAZZ) stock price?
JAZZ is trading at $210.23 at the last market close, down 1.95% on the session. PreMarketPrice tracks JAZZ pre-market, intraday and after-hours prices.
Is JAZZ stock a buy right now?
PreMarketPrice's quantitative model rates Jazz Pharmaceuticals, Inc.'s financial health at 40/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is JAZZ stock overvalued?
Jazz Pharmaceuticals, Inc. trades at a trailing P/E of 14.5 and our valuation score rates it 82/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Jazz Pharmaceuticals, Inc. report earnings?
No confirmed earnings date is currently scheduled for JAZZ. The Earnings section lists recent reports and updates as dates are announced.
What sector does Jazz Pharmaceuticals, Inc. operate in?
Jazz Pharmaceuticals, Inc. operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Jazz Pharmaceuticals, Inc. do?
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology.
About Jazz Pharmaceuticals, Inc. (JAZZ) Stock
Jazz Pharmaceuticals, Inc. (JAZZ) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Jazz Pharmaceuticals, Inc. is trading at $210.23, down 1.95% on the day with a market capitalization of $13.7 billion. The financial health score for JAZZ is 40/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for JAZZ stock.
JAZZ Stock Analysis & Key Metrics
On PreMarketPrice, you can track Jazz Pharmaceuticals, Inc. (JAZZ) across multiple dimensions:
- Pre-market price & movement: Real-time JAZZ stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for JAZZ with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Jazz Pharmaceuticals, Inc. across multiple reporting periods.
- Financial health score: A composite score of 40/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for JAZZ.
- Sector peers: Compare JAZZ against 6 other healthcare stocks on key financial metrics.
Is JAZZ a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Jazz Pharmaceuticals, Inc. (JAZZ) as an investment. The financial health score of 40/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Jazz Pharmaceuticals, Inc. (JAZZ) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.